Skip to main content
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. — Investor Relations & Filings

Ticker · OVID ISIN · US6904691010 LEI · 549300H36NUI4L6U8F17 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2023-11-03 Interim / Quarterly Rep…
Country US United States of America
Listing US OVID

About Ovid Therapeutics Inc.

https://ovidrx.com/

Ovid Therapeutics Inc. is a biopharmaceutical company that develops targeted small molecule therapies for neurological conditions. The company's primary focus is on conquering epilepsies and other brain disorders by creating treatments that aim to reduce seizures and offer improved safety and tolerability. Ovid's scientific approach involves pioneering compounds with unique or potentially best-in-class mechanisms of action to address significant unmet medical needs. The company's mission is to develop medicines that improve the lives of patients and families affected by these conditions.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2023
2023-11-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Ovid Therapeutics Inc. It announces the issuance of a press release regarding Third Quarter 2023 Financial Results and Corporate Updates. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length is 3657 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such filings that do not fit other specific categories.
2023-11-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a Purchase and Sale Agreement) involving the sale of certain royalty and milestone payment rights. It also includes a press release and forward-looking statements. There are no detailed financial statements or comprehensive financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7263 characters) and content confirm it is not merely a report publication announcement but a substantive filing. Confidence is high due to clear identification of the form and content.
2023-10-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 2, 2023. It announces that Ovid Therapeutics Inc. presented a corporate presentation on that date, which will be posted on their website and is filed as an exhibit to this report. The text does not contain the presentation itself but refers to it and states it is incorporated by reference. The document length is 3097 characters, which is relatively short and consistent with an announcement rather than the full presentation. According to the classification rules, announcements of presentations or reports that are short and refer to the report being attached or available elsewhere should be classified as Regulatory Filings (RNS) rather than Investor Presentation (IP). Therefore, this document is best classified as a Regulatory Filing (RNS).
2023-10-02 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2023, for Ovid Therapeutics Inc. It announces the issuance of a press release regarding the Second Quarter 2023 Financial Results and Corporate Updates. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release (Exhibit 99.1) that is furnished as part of the filing. The length of the document is 3648 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results and corporate updates.
2023-08-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.